American Society of Clinical Oncology
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
A personalized vaccine for melanoma cut the risk of cancer returning after five years
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.
China’s Rise in Drug Development Looms Over U.S.
The American Society of Clinical Oncology annual meeting in Chicago last year. One of the conference’s coveted headliners this year will be a presentation of a clinical trial conducted only in China.
China’s Rise in Drug Development Looms Over U.S.
The American Society of Clinical Oncology annual meeting in Chicago last year. One of the conference’s coveted headliners this year will be a presentation of a clinical trial conducted only in China.
China’s Rise in Drug Development Looms Over U.S.
The American Society of Clinical Oncology annual meeting in Chicago last year. One of the conference’s coveted headliners this year will be a presentation of a clinical trial conducted only in China.
Could cancer vaccines be next? New treatment cuts melanoma risk by nearly 50%
A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna. The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.CLICK HERE FOR MORE HEALTH STORIESAfter about a five-year...
Cancer breakthrough bonanza: Does string of advances signal turning point?
Cancer breakthrough bonanza: Does string of advances signal turning point? Issued on: It’s not every day that a standing ovation at a medical conference goes viral. Dateline Chicago and the annual conference of the American Society of Clinical Oncology.
Removing ‘invisibility cloaks’ and safely skipping chemo: new weapons in war on cancer shared at US conference
Drug that stops cancer cells hiding and a breakthrough for pancreatic cancer among highlights from Asco conference – but there were also notes of cautionDoctors, scientists and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world’s largest cancer conference. The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year’s theme,...
Removing ‘invisibility cloaks’ and safely skipping chemo: new weapons in war on cancer shared at US conference
Drug that stops cancer cells hiding and a breakthrough for pancreatic cancer among highlights from Asco conference – but there were also notes of cautionDoctors, scientists and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world’s largest cancer conference. The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year’s theme,...
Weight-loss drugs may cut breast cancer risk by up to 30%, study finds
Women on weight-loss medication may have a lower risk of developing breast cancer, according to a new study. Women who take GLP-1 medications, such as Ozempic or Mounjaro, are less likely to develop breast cancer, a new study has found. The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, come from an analysis of more than 110,000 women aged between 45 and 80.
Cancer survivors saw major improvements in sleep and well-being with one weekly practice
Yoga is known to boost relaxation, strength and flexibility – and now a new study has found the practice could improve cancer survivors’ quality of life. A randomized trial led by the University of Rochester Medical Center found that a four-week yoga program significantly reduced insomnia, fatigue, anxiety and mood disturbances after cancer treatment. The findings were presented last week at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.